Clinical significance of peripheral blood UL16 and DR-70 for the early diagnosis and prognostic evaluation of colorectal cancer

doi:10.4251/wjgo.v16.i9.3832

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (76)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-4)

Sum=63

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=11

Sep 15, 2024 (publication date) through Sep 10, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Gastrointest Oncol. Sep 15, 2024; 16(9): 3832-3838
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3832

Clinical significance of peripheral blood UL16 and DR-70 for the early diagnosis and prognostic evaluation of colorectal cancer

Zhi-Ping Zong, Chen Wu

Zhi-Ping Zong, Department of Blood Transfusion, Affiliated Hospital of Jiangnan University, Wuxi 214000, Jiangsu Province, China

Chen Wu, Clinical Laboratory, Jiangsu Province Official Hospital, Nanjing 210003, Jiangsu Province, China

Author contributions: Zong ZP and Wu C designed the study; Zong ZP and Wu C analyzed the data; Zong ZP performed data collection and wrote the manuscript; all authors have read and approved the final manuscript.

Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of the Affiliated Hospital of Jiangnan University.

Informed consent statement: All study participants or their legal guardians provided written informed consent prior to their participation in this study.

Conflict-of-interest statement: The authors declare no conflicts of interest.

Data sharing statement: No additional data are available.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Chen Wu, BMed, Technician, Clinical Laboratory, Jiangsu Province Official Hospital, No. 65 Jiangsu Road, Gulou District, Nanjing 210003, Jiangsu Province, China. 15251848843@163.com

Received: July 15, 2024
Revised: August 13, 2024
Accepted: August 14, 2024
Published online: September 15, 2024
Processing time: 55 Days and 15.4 Hours

Core Tip

Core Tip: The combination of Peripheral blood UL16-binding protein 2 (ULBP2) and human fibrinogen degradation products (DR-70) can obviously improve the diagnostic value of early colorectal cancer (CRC), which is very important for the early diagnosis and treatment of CRC. This study confirmed the diagnostic value of serum ULBP2 and DR-70 levels in early CRC patients by observing their serum ULBP2 and DR-70 levels.